Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $2.16, but opened at $2.24. Autolus Therapeutics shares last traded at $2.27, with a volume of 119,994 shares.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AUTL shares. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Up 5.3 %

The firm has a market capitalization of $605.35 million, a price-to-earnings ratio of -1.88 and a beta of 2.05. The stock’s 50-day moving average price is $2.63 and its 200 day moving average price is $3.53.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the business posted ($0.26) EPS. On average, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AUTL. Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $47,000. Avanza Fonder AB acquired a new position in Autolus Therapeutics during the 4th quarter worth $75,000. Hennion & Walsh Asset Management Inc. acquired a new position in Autolus Therapeutics during the 4th quarter worth $611,000. JPMorgan Chase & Co. increased its position in shares of Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after purchasing an additional 761,008 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.